NR1H4 and fatty liver disease: These findings suggest that inhibiting intestinal FXR reduces the synthesis and production of intestine-derived ceramides, thereby contributing to the beneficial effects of DC646 on metabolic dysfunction-associated fatty liver disease (MAFLD).